The dyslipidemia drug that received industry attention as a first-in-class siRNA drug is facing difficulties in obtaining insurance reimbursement coverage in Korea.

According to Dailpharm’s coverage, Novartis Korea's Leqvio (inclisiran) applied for new drug reimbursement after receiving approval from the Ministry of Food and Drug Safety in June, but during the Health Insurance Review and Assessment’s review process, the company and the government, especially the medical community and the government, were found to have major differences in opinion in setting the reimbursement standards.

The government is considering reimbursing the drug for the rare disease, familial hypercholesterolemi